Intellia Therapeutics Inc
NTLA
Market Cap$2.4B
Close$
$-4.76
122.1% downside
Current Fair Value
122.1% downsideOvervalued by 122.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.40 Billion |
|---|---|
| Enterprise Value | $1.49 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-5.42 |
| Beta | 1.85 |
| Outstanding Shares | 96,106,405 |
| Avg 30 Day Volume | 1,272,391 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -5.0 |
|---|---|
| PEG | -30.21 |
| Price to Sales | - |
| Price to Book Ratio | 2.15 |
| Enterprise Value to Revenue | 41.11 |
| Enterprise Value to EBIT | -2.81 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
ESG Score
No data
About Intellia Therapeutics Inc
211 employees
CEO: John Leonard Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and Virginijus Šikšnys . The company has partnerships with Novartis and Regeneron. Intellia Th...